Lv Y, Luo WJ. Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes. World J Clin Cases 2024; 12(22): 5008-5015 [PMID: 39109007 DOI: 10.12998/wjcc.v12.i22.5008]
Corresponding Author of This Article
Wei-Jun Luo, BMed, Associate Chief Physician, Department of Cardiology, Lishui People's Hospital, No. 15 Mass Street, Liandu District, Lishui 323000, Zhejiang Province, China. lwj18957091539@163.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 6, 2024; 12(22): 5008-5015 Published online Aug 6, 2024. doi: 10.12998/wjcc.v12.i22.5008
Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes
Yuan Lv, Wei-Jun Luo
Yuan Lv, Wei-Jun Luo, Department of Cardiology, Lishui People's Hospital, Lishui 323000, Zhejiang Province, China
Author contributions: Lv Y conceived the entire study and wrote the article; Luo WJ collected the data and completed the analyses; All authors reviewed the manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Lishui People's Hospital.
Informed consent statement: The data used in this study did not involve patients' private information, and all patient data were obtained, recorded, and managed for the sole purpose of this study and without causing any harm to the patients. Therefore, the Ethics Committee of Lishui People's Hospital has waived the requirement of informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Jun Luo, BMed, Associate Chief Physician, Department of Cardiology, Lishui People's Hospital, No. 15 Mass Street, Liandu District, Lishui 323000, Zhejiang Province, China. lwj18957091539@163.com
Received: May 7, 2024 Revised: June 9, 2024 Accepted: June 18, 2024 Published online: August 6, 2024 Processing time: 55 Days and 20.4 Hours
Core Tip
Core Tip: This study explored the efficacy of combining dapagliflozin and sakubactrovalsartan (noxinto) in improving myocardial microperfusion and reducing major adverse cardiovascular event incidence in patients with post–acute myocardial infarction (AMI) heart failure and type 2 diabetes mellitus (T2DM). Results indicated that compared with the control group, significant improvements in myocardial perfusion, blood glucose levels, and cardiac function along with reductions in N-terminal pro-atrial natriuretic peptide, growth differentiation factor-15, and high-sensitivity C-reactive protein levels were noted in the observation group. These findings revealed that this combination therapy may offer a novel approach for managing complex cases of post-AMI heart failure and T2DM, highlighting its potential benefits and mechanisms of action.
